Schoenberg Mark's Form 4 filing
UroGen Pharma Ltd. (URGN) · filed Feb 4, 2026
- Accession no.
- 0001437749-26-003040
- Filed
- Feb 4, 2026
- Trade date
- Feb 3, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $145.2K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schoenberg MarkCIK 0001763581 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | Ordinary Shares | SSaleDisposed | −1,844 | $19.69 | −$36,308.36 | 150,514 | Direct | |
| Feb 3, 2026 | Ordinary Shares | SSaleDisposed | −1,843 | $19.69 | −$36,288.67 | 148,671 | Direct | |
| Feb 3, 2026 | Ordinary Shares | SSaleDisposed | −3,686 | $19.69 | −$72,577.34 | 144,985 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.